Jaine Brownell, MD
Payments from drug & device makers
Across 628 payments — averaging $30.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- CSL Behring$4K
- Sanofi$2K
- GSK$1K
- Pfizer$813
- Regeneron Healthcare Solutions, Inc.$787
- plus $5K from 32 others
What the payments were for
- Consulting fees$5,92531%
- Travel & lodging$1,5348%
- Food & beverage$11,60260%
- Education$1911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 30 | $4,983 |
| CSL Behring | 35 | $3,829 |
| Sanofi | 102 | $2,098 |
| GSK | 110 | $1,253 |
| Pfizer | 51 | $813 |
| Regeneron Healthcare Solutions, Inc. | 36 | $787 |
| AstraZeneca | 24 | $778 |
| AbbVie | 39 | $677 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $622 |
| Biocryst US Sales Co., LLC | 26 | $515 |
| Amgen(2 entities) | 20 | $376 |
| Pharming Healthcare, Inc. | 19 | $343 |
| Grifols USA, LLC | 15 | $311 |
| Novartis | 17 | $288 |
| Alk-abello, Inc | 6 | $207 |
| Sanofi-aventis U.S. LLC | 3 | $180 |
| Hospira, Inc. | 9 | $143 |
| Shire North American Group Inc | 1 | $119 |
| Optinose US, Inc. | 6 | $115 |
| Blueprint Medicines Corporation | 4 | $104 |
| Kaleo, Inc. | 7 | $95 |
| Incyte Corporation | 5 | $83 |
| Galderma Laboratories, L.p. | 5 | $77 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $62 |
| Lilly USA, LLC | 3 | $61 |
| Bio Products Laboratory USA, Inc. | 3 | $49 |
| Octapharma USA, Inc. | 2 | $44 |
| Cycle Pharmaceuticals Inc | 2 | $36 |
| Covis Pharma GmbH | 2 | $31 |
| Ionis Pharmaceuticals, Inc. | 2 | $30 |
| Boehringer Ingelheim | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| LEO Pharma Inc. | 1 | $21 |
| GC Biopharma USA, Inc. | 1 | $17 |
| Organon | 1 | $15 |
| Biocryst Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IcatibantIcatibant Acetate | 15 | $826,668 |
| TakhzyroLanadelumab-Flyo | 14 | $726,756 |
| Dupixent SyringeDupilumab | 39 | $150,253 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 156 | $111,958 |
| TezspireTezepelumab-Ekko | 12 | $53,834 |
| NucalaMepolizumab | 12 | $50,850 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $20,833 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $11,534 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $9,232 |
| Arnuity ElliptaFluticasone Furoate | 29 | $9,059 |
| DuleraMometasone/Formoterol | 18 | $6,553 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,232 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,042 |
| AlvescoCiclesonide | 12 | $3,294 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $2,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $622 | $726,75614 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $1,253 | $192,700240 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $778 | $71,59970 claims |
| MerckDulera | $14 | $6,55318 claims |
| Covis Pharma GmbHAlvesco | $31 | $3,29412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Nebraskaon file to place this against a meaningful peer group, so we don't.
Other allergy in Omaha
- Ebrahim ShakirOmaha$5K
- Jenna EssinkLincoln$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.